
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Detroit - Topical treatment allows medication delivery directly to the skin with reduced systemic exposure compared to orally administered agents, but local drug application is not without risk to internal organ systems, according to Peter J. Aronson, M.D.






